FTO.nl maakt op haar websites gebruik van cookies. Een cookie is een klein bestandje dat met een pagina van een website wordt meegestuurd en door uw browser (tijdelijk) op de harde schrijf van uw computer of mobiele apparatuur wordt opgeslagen.
Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union. Medical management, epidemiology and economic burden. Arch Osteoporos. 2013;8:136.
Van Helden S, van Geel ACM, Geusens PP, et al. Bone and fall-related fracture risks in women and men with a recent clinical fracture. J Bone Joint Surg Am. 2008;90(2):241-248.
Center JR. Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal About Clinical Outcomes of Osteoporosis. Curr Osteoporos Rep. 2017;15(2),88-95 (2017).
Gehlbach S, Saag KG, Adachi JD, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. J Bone Miner Res. 2012;27(3):645-653.
Van der Jagt-Willems HC, Van Hengel M, Vis M, et al. F. Why do geriatric outpatients have so many moderate and severe vertebral fractures? Exploring prevalence and risk factors. Age Ageing 2012;41:200-206.
Ott SM. Cortical or Trabecular Bone: What’s the Difference? Am J Nephrol. 2018;47(6): 373–375.
Lems WF, Van den Bergh JP, Elders PJM, et al. Osteoporose en fractuurpreventie: van evidence-based medicine naar spreekkamer. Hoofdstuk 1. Botstructuur en botkwaliteit. Heemstede: DCHG Medische Communicatie, 2016; ISBN:978-94-90826-44-4.
Genant HK, WU CY, van Kuijk C, et al. Vertebral fracture assesment using a semiquantitative rechnique. J Bone Min Res 1999; 8(9): 1137-1148.
Merlijn T, Swart KMA, van der Horst HE, et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporosis Int. 2020;31:251-257.
Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis international, 2000;11(1), 83-91.
Lötters FJ, Van den Bergh JP, De Vries F, Rutten-van Mölken MP. Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int 2016;98:235-43.
Van der Velde RY, Bours SPG, Wyers CE, Lems WF, Geusens PPMM, Van den Bergh JPW. Effect of implementation of guidelines on assessment and diagnosis of vertebral fractures in patients older than 50 years with a recent non-vertebral fracture. Osteoporos Int 2017;28:3017-22.
Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993-1000.
Van Staa, TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis & Rheumatism. 2003;48:3224-3229.
Pluijm SM, Koes B, De Laet C, et al. A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies. J Bone Miner Res. 2009;24:768-774.
Oudshoorn C, van der Cammen TJ, McMurdo ME, et al. Aging and vitamin D deficiency: effects on calcium homeostasis and considerations for vitamin D supplementation. Br J Nutr. 2009;101(11):1597-1606.
Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial. JAMA Intern Med. 2016;176(2): 175-183.
Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015;351:h4580.
Topf JM, Murray PT. Hypomagnesemia and hypermagnesemia. Rev Endocr Metab Disord. 2003;4:195-206.
Mott A, Bradley T, Wright K, et al.Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporosis International. 2019;1-17.
Zhang Y, Liu Z, Duan L, et al. Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study. Calcified Tissue International. 2020;110.
van Helden S, van Geel AC, Geusens PP, et al. Bone and fall-related fracture risks in women and men with a recent clinical fracture. J Bone Joint Surg Am. 2008;Feb;90(2):241-248.
Huntjens KM, van Geel TA, van Helden S, et al. The role of the combination of bone and fall related risk factors on short-term subsequent fracture risk and mortality. BMC Musculoskelet Disord. 2013;14:121.
Meekes WM, Leemrijse CJ, Weesie YM,et al. Falls prevention at GP practices: a description of daily practice. BMC Fam Pract. 2021;22:190.
Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1623-1630.
Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190-198.
Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2021;106(1): 264-281.
Everts-Graber J, Reichenbach S, Ziswiler HR, et al. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. Bone Miner Res. 2020;35(7):1207-1215.
Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513-523.
Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938.
Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-254.
Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1595-1622.
Merlijn T, Swart KM, Van Schoor NM, et al. The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res. 2019;34:1993-2000.
ZSwart KMA, Van Vilsteren M, Van Hout W, et al. Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in 900 primary care: a qualitative study. BMC Fam Pract. 2018;23;19:141.
Salminen H, Piispanen P, Toth-Pal E. Primary care physicians' views on osteoporosis management: a qualitative study. Arch Osteoporos. 2019;26;14:48
Materialen aanvragen voor Osteoporose en fractuurpreventie
FTO Onderwerpen
FTO
